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Background: In this report we present the results of the retrospective (survival and classification) analyses of
possible prognostic factors prolonging survival in epithelial ovarian cancer brain metastases patients after
stereotactic radiotherapy. We focus on a wide range of available predictors to establish survival in patients with a
good health status and no more than three lesions.
Methods: Two parallel statistical methods in survival analysis were used: classical and Bayesian methods to verify
statistical results. To display the predicted and posterior survivals, classification trees were built.
Results: From the initial set of prognostic factors, only four were established as statistically significant in
multivariate regression. They were: survival to metastases to brain after epithelial ovarian cancer diagnosis, number
of metastases at diagnosis, central nervous system radiotherapy prior to stereotactic radiotherapy, and interval to
stereotactic radiotherapy after metastases diagnosis.
Conclusions: When considering evidence-based standards of treatment of patients suffering from epithelial ovarian
cancer brain metastases, the established clinical factors are suggested to be prognostic.
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Classification treeBackground
Brain metastases (BMs) from epithelial ovarian cancer
(EOC) are rare (approximately from one to a several per-
cent [1-5]), but diagnosis of this occurrence is increasing
in recent years [6-8], probably owing to more effective
treatment of the primary cancer and the resulting pro-
longation of survival [2]. However, the prognosis for pa-
tients with BM from EOC is poor [9-11,4].
In the last few decades many investigations have been
carried out to gain a better understanding of the mechan-
ism of ovarian cancer brain dissemination and different
factors have been established but partly with conflicting
results [4]. However, due to the small number of patients
considered in these studies [12-14], randomized treatment
evaluations specific for this histology are not possible [2].* Correspondence: acelejewska@wp.pl; atukiendorf@io.gliwice.pl
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article, unless otherwise stated.Therefore, in order to critically evaluate underlying risk
factors and the clear benefit of treatment options, multi-
center clinical trials are needed in further investigation [9].
Only two factors were able to gain acceptance of most
authors publishing in the current literature on the sub-
ject [4]. One factor is the presence of an extracranial dis-
ease at the time of brain relapse, which was shown to
have a significantly negative impact on survival. The
other factor is the performance status of patients at the
time of recurrent disease [2,4]. Moreover, a short time
interval between primary diagnosis and the brain relapse
was reported to have a negative impact on survival [4].
An alternative univariate analysis has shown that extraper-
itoneal metastases at the time of the diagnosis of brain
metastases are adversely correlated with survival [2] (these
results comply with those of [13]). Some authors report
that the Fédération Internationale de Gynécologie et d’Ob-
stétrique (FIGO) stage has been correlated with increased
incidence of brain metastasis [12,15].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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the past, such as age at diagnosis, time interval between
primary diagnosis and metastatic manifestation, number
of BMs, tumor stage, grade, histotype, degree of histo-
logical differentiation and site of lesion of central ner-
vous system (CNS) relapse, it is widely agreed in the
current literature that these are not related to survival
[4,10,13,9,16]. What is more, CA125, a useful biomarker
for detecting relapse of ovarian cancer, has a limited
value in detection of brain metastases [17-19,5] (theor-
etically, because the blood–brain barrier may hinder the
relatively large CA125 molecule produced by cerebral
lesions from gaining access to systemic blood circula-
tion [5]).
Considering that brain dissemination in ovarian can-
cer is generally a palliative situation, quality of life
should be one of the main objectives that has to be
taken into account in the decision on the optimal ther-
apy strategy. All the patients report discomfort after
treatment [4], and no definite therapeutic modality can
be inferred [5]. A multi-modal approach using surgery,
radiation and chemotherapy (CT) has been suggested
in several reports. The standard treatment consists of
full brain radiotherapy (WBRT), which was shown to
improve the quality of life by reduction of neurological
symptoms and appears to result in a prolongation of
survival [18,10]. There was a statistically significant
difference in survival for those treated with WBRT plus
CT versus those treated with WBRT alone, and those
undergoing supportive care only [3]. However, most
CT related side-effects result in a decrease of a pa-
tient’s quality of life.
In the last few years stereotactic radiosurgery (SRS –
with a single fraction) as well as stereotactic radiotherapy
(SRT – with a high-dose radiation fraction) have come
into focus as other promising therapy options in brain me-
tastases from ovarian cancer [4] (in our paper both defined
as SRT). Some authors [11] even describe the observed re-
markable median survival after treatment with SRS as
compared to WBRT. Indeed, SRT is now considered by
many groups to be an alternative to surgery for focal con-
trol of cerebral metastases in certain situations, and has
become increasingly popular [20] as another promising
therapy option or even optimal treatment [21,11,22]. The
presented radiotherapeutic direction is consistent with
that presumed in the initial report on the EOC BM pa-
tients advocating that “prompt aggressive therapy of the
CNS metastasis may provide not only adequate palliation,
but prolonged survival” [1].
In the present study, we reviewed our experience with
EOC BM patients who underwent SRT. The aim of the
study was to evaluate the efficacy of the EOC BM treat-
ment in patients after SRT and to investigate possible
prognostic factors of survival.Material and methods
The analyzed material (with obtained consent) com-
prised of 32 patients (in comparison with 23 in [13], or
12 in [20]) who were diagnosed with BM from EOC and
underwent SRT in the Cancer Center and Institute of
Oncology in Gliwice, Poland, between 2003 and 2013
(with a prior EOC diagnosis since 1998). General char-
acteristics of patients (with basic description statistics)
classified in the following groups of risk factors are: age,
clinical, pathological, imaging, treatment, and follow-up
outcome, as presented in Table 1.
Altogether, over 30 continuous, binary, ordered, and cat-
egorical variables were taken into account (see Table 1).
In particular, wide ranges of CA125 protein concen-
trations were observed before CT, while their levels de-
creased after treatment. 28 of 32 patients were classified
by the FIGO staging of ovarian carcinomas (17 cases
with IIIC stage), and in 26 of those the tumor differenti-
ation was examined (16 patients had prevailingly G3
grading).
Imaging analyses were conducted in all patients (16
following computer tomography, and the remaining half
following magnetic resonance). Of those, in 14 patients a
single BM was detected, 12 of them had 2 BMs, and 6
patients were diagnosed with 3 BMs.
With respect to RT, after BM diagnosis, 23 patients
were irradiated with SRS dose of 8–24 Gy, and 9 of them
underwent SRT in 2–3 fractions of 12–24 Gy doses. A
large number of patients (22) received WBRT with the
most frequent fractionation schedule 5 × 4 Gy (17 of
them had WBRT prior to SRT, and 5 post-SRT). Prior to
SRT, 5 patients had also undergone surgical resection.
The Kaplan-Meier survival curves in a combined plot
are presented in Figure 1.
In comparison, according to the different types of lesions,
the median of BM free survival (BMFS) = 15.9 months was
observed in Greek patients [3], 22 months in a Taiwanese
study [8], and 57 months in patients with grade I and II tu-
mors in an Israeli investigation [2]. In turn, the post-BM
survival ranged from 2 months in patients on corticoste-
roids [2], to 29 months in patients after treatment with
SRT [11].
Relationships between possible risk factors and sur-
vival after SRT were tested using available modern statis-
tical methodology. In the survival analysis, the Weibull’s
regression [23] has been applied. The results were pre-
sented as hazard ratios with 95% confidence/credible in-
tervals following both classical (frequentist) [24] and
Bayesian (simulation) approaches [25].
Subsequently, the respective predicted and posterior
survivals from classical and Bayesian models, were used
to build classification trees of patients [26]. In the ana-
lysis, “rpart” statistical package [27] of the R software
[24] was implemented.
Table 1 Data on EOC BM patients
Characteristics Risk factor Mean SD Median Q1 Q3 Min. Max.
Age at EOC diagnosis 52.6 9.3 54 47 59.3 27 67
at SRT 56.3 9.2 56.5 50.8 62 35 77
Clinical CA125 before CT1 [U/mL] 1578 2317 740 151 1946 19 9693
CA125 after CT1 [U/mL] 29 69 13 8 17 2 318
CA125 before CT2 [U/mL] 566 791 190 84 690 38 2407
CA125 after CT2 [U/mL] 73 143 22 10 57 9 496
CA125 before SRT [U/mL] 132 189 56 25 139 8 533
ZUBROD 1.2 0.4 1 1 1 1 3
FIGO IIIC IIIA IIIC IA IVA
Tumor grade [G] 2.6 0.5 3 2 3 2 3
Histopathology: adenocarcinoma serosum = 53%, adenocarcinoma endometroides = 25%,
cystadenocarcinoma mucinosum = 6%, non-differentiated = 13%, not examined = 3%
Imaging No. of BMs at diagnosis 1.8 0.8 2 1 2 1 3
Total PTV at diagnosis [cm3] 9.7 14.8 5.1 1.6 10.0 0.4 62.1
Relapse out of CNS 47%
Localisation supratentorial = 25%, infratentorial = 63%, supratentorial/infratentorial = 12%
Treatment from EOC diagnosis to CT1 [weeks] 6.6 5.9 5 3 8 0 28
CT1 duration [weeks] 19.6 5.6 18 17 20 12 38
CT2 duration [weeks] 8.5 10.4 0 0 17 0 34
Total CT duration (CT1 + CT2) [weeks] 27.7 13 23 18 35 12 72
No. of CT1 cycles 6.1 0.8 6 6 6 5 9
No. of CT2 cycles 2.4 2.9 0 0 5.5 0 9
Total no. of CT cycles (CT1 + CT2) 8.5 3.2 6 6 11.5 5 18
Surgery 22%
WBRT before SRT 53%
WBRT after SRT 16%
BM to SRT [months] 22 26.9 8 4.8 36 1 117
BM to SRT (above 1 month) 75%
Follow-up outcome from EOC diagnosis to BM [months] 29.5(CI95% = 25–44)
from BM to death [months] 16(CI95% = 8–21)
from SRS to death [months] 7(CI95% = 6–18)
from EOC diagnosis to death [months] 49(CI95% = 45–69)
Deaths during observation 94%
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The results of multivariate analyses of survival after SRT
are reported in Table 2.
In the multivariate regression analysis, only four possible
risk factors were found that might have an influence on
the risk of early death after EOC BM diagnosis in the ana-
lyzed group of patients and, worthy of note, they are
nearly identical both in the classical and Bayesian ap-
proaches (see Table 2). Interpretation of the results is as
follows: each additional month of BMFS resulted in the
2% increase of risk of death in patients after a disease me-
tastasis; if the difference was one year, then the riskincreased up to (1.02212–1)*100% = 30%. The number of
metastases may also elevate the risk of death in EOC pa-
tients: in those with 2 BMs, the risk is nearly twice as
high compared with patients suffering from 1 BM only,
according to both classical and Bayesian approaches;
whereas in patients with 3 BMs the risk was approxi-
mately 4 times higher than in those with 1 BM after the
metastasis. WBRT applied prior to SRT significantly de-
layed death of patients after BM; the risk of early death
was reduced by over ¾. Worthy of note, delayed SRT, lon-
ger than 1 month after BM diagnosis, drastically (at least
20 times) increased the risk of death in EOC patients. The
Figure 1 Survival in EOC BM patients.
Celejewska et al. Journal of Ovarian Research 2014, 7:79 Page 4 of 7
http://www.ovarianresearch.com/content/7/1/79obtained relationships for predicted outcomes in different
dimensions (with exponential approximations) for classical
and Bayesian approaches are presented graphically in
Figures 2, 3 and 4.
It can be seen in Figures 2, 3 and 4 that SRT consider-
ably increased median survival in EOC BM patients,
however, a reducing effect can be observed with time to
metastasis. The best prognosis is expected for patients
with a single BM, whereas in those with 2 or 3 lesions,
the survival after the SRT treatment decreases radically.
Following the models, in patients who had BMFS for ap-
proximately 5 yrs., a beneficial effect of WBRT prior to
SRT for survival was observed. However, reduced time
to SRT after BM diagnosis is the strongest argument for
the survival prolongation. Finally, based on the Weibull’s
regression parameters strong coherence between the
classical and Bayesian methods can be established.Table 2 Multivariate Weibull’s regression
Method: Classical
Risk factor Hazard ratio Confidence 95% interval
Time from EOC diagnosis to BM 1.022 (1.007,1.039)
Number of BMs 1.931 (1.202,3.102)
WBRT prior to SRT 0.211 (0.07,0.635)
Interval to SRT longer than 1
month vs. shorter than 1 month
20.06 (6.016,66.91)The plots of classification trees of the predicted and pos-
terior survivals in EOC BM patients after SRT for the clas-
sical and Bayesian approaches are presented in Figure 5.
Following classification trees (Figure 5), it can be
ascertained that interval to SRT after metastasis is also a
basic factor for the modeled (classical and Bayesian) sur-
vivals; prompt SRT provided the longest median survival
reaching approximately 30 months. In case of longer ex-
pectation for SRT (>1 month), one-year survival with a
prior WBRT is predicted. The poorest (four-month) sur-
vivals were observed in patients with longer interval for
SRT and with no prior WBRT.
Discussion
Defining possible clinical and medical factors is a very dif-
ficult research task, so is standardization of treatment
prolonging survival in EOC BM patients. ContemporaryBayesian
p-Value Hazard ratio Credible 95% interval p-Value (one-sided)
0.0051 1.022 (1.005,1.037) 0.0054
0.0065 1.999 (1.150,3.266) 0.006
0.0057 0.249 (0.065,0.674) 0.0054
<0.0001 28.02 (5.003,88.83) <0.0001
Figure 2 Median survival since SRT vs. time from EOC to BM stratified by BM numbers.
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much consistent in worked conclusions. What is more,
already established prognostic factors often did not pass
the multivariate analysis [13,18,4]. The reason for such
situation is a clinical specificity and epidemiological rarity
of the disease. Our results based on the multivariate re-
gression confirm previous reports and show some novelty.
Disputable appears to be an inverse correlation be-
tween BMFS and survival after SRT. Our result is oppos-
ite to [13] who report a median survival of 9 months in
patients with BMFS < 40 months, and 16 months after
SRT, if BMFS > 40 months. There are two possible expla-
nations for longer survival after SRS/SRT and short
BMFS. What is important, brain metastases are a crucial
factor influencing survival of ovarian cancer patients, how-
ever not the only one. Clinical situation of solitary brain
metastasis as only one location of cancer is extremely rare
and possibility of presence of other metastases increases
with time after the basic treatment completion. In aFigure 3 Median survival since SRT vs. time from EOC to BM stratifieddisseminated disease also the other metastases limit sur-
vival, what could partially explain this situation. The sec-
ond reason for such correlation can be a delay in brain
metastases diagnosis, what is linked to their volume and
to limited survival (longer time to diagnosis – larger
tumor – shorter survival).
The number of lesions to the brain is another most
probable risk factor of survival. Our result is consistent
with [18] who describes a slight advantage of a solitary
lesion over presentation with multiple lesions (with a me-
dian survival of 7 versus 5 months at a liberal p-Value =
0.07 [18]). This result is in an absolute agreement with
logic and neoplastic disease biology. More metastases
(more cancer clonogenic cells) is always connected to
shortened survival; especially in the case of brain mets lo-
cated in a limited volume of skull. Exactly the same results
are obtained in other cases of cancers.
A novel finding of our study is WBRT before SRT,
which has never been reported so far in case of EOCby prior WBRT.
Figure 4 Median survival since SRT vs. time from EOC to BM stratified by interval to SRT.
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other primary tumor sites [28]). We estimated a beneficial
effect of preceding WBRT in patients with BMFS > 5 years
(post-SRT WBRT did not bring any statistical effects on
survival). This result could be biased by a retrospective
character of this study and patient selection. Probably, a
greater number of ovarian cancer patients were treated in
this period with WBRT because of brain mets; but only
few, very well responding, had following SRS/SRT. Good
individual response to radiation probably impacted the
survival. Additionally, late presence of BM, can be linked
to a lesser aggressiveness of the (individual) disease itself.
Since publication of the original study [1], most of the
reports support the thesis of a prompt aggressive radio-
therapy as very promising in the disease treatment. We do
support this opinion but SRT must be conducted immedi-
ately after BM diagnosis (<1 month). Then, it may consid-
erably affect the disease development and extend life
expectancy. Because a remarkable median survival of
29 months after SRT compared to 6 months after WBRT
was observed in [11], we suggest to use the RT techniques
together, as opposed to SRT alone. As aforementioned, the
impact of WBRT-SRS/SRT combination could be influ-
enced by patient selection and individual features of par-
ticular cancers, however, considering a systemic characterFigure 5 Classification trees of the classical and Bayesian median survof ovarian cancer (similarly as in, for example, small cell
lung cancer), we can expect better results of combined RT
modality with a relatively short gap (elective effect of
WBRT + local additive effect of WBRT/SRT combination).
In classification analysis, the applied statistical algo-
rithm has “chosen” RT schedules (expectation interval
for SRT and prior WBRT in the order of importance) as
more effective than other, found in this study, risk fac-
tors (BMFS and number of BMs). This fact magnifies
medical supremacy of radiotherapy in cancer treatment.
Conclusions
Based on the experience from Cancer Center and Insti-
tute of Oncology in Gliwice, we can draw the following
conclusions:
 prompt SRT may prolong survival in EOC BM
patients;
 additional prior WBRT is suggested in patients who
had BMFS > 5 years;
 BMFS and number of BMs are reliable prognostic
factors of survival;
 multiclinic trials and cooperation in the future
may extend the medical knowledge on the
considered problem.ivals.
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